Eton Pharmaceuticals (ETON) Retained Earnings (2017 - 2026)

Eton Pharmaceuticals has disclosed Retained Earnings across 10 years of filings, most recently posting -$99.4 million for Q2 2026.

• In Q2 2026, Retained Earnings fell 173.07% year-over-year to -$99.4 million; the TTM figure through Jun 2026 stood at -$99.4 million (down 173.07% YoY), while the FY2025 annual figure was -$112.5 million, down 4.26% from the prior year.
• Retained Earnings came in at -$99.4 million for Q2 2026 at Eton Pharmaceuticals, up from -$112.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $137.1 million in Q3 2025 to a low of -$112.5 million in Q4 2025.
• Average Retained Earnings over 5 years is -$76.3 million, with a median of -$104.0 million recorded in 2022.
• Year-over-year, Retained Earnings jumped 227.76% in 2025 and sank 173.07% in 2026.
• Over 5 years, Retained Earnings stood at -$103.1 million in 2022, then declined by 0.91% to -$104.1 million in 2023, then decreased by 3.67% to -$107.9 million in 2024, then dropped by 4.26% to -$112.5 million in 2025, then gained by 11.67% to -$99.4 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$99.4 million in Q2 2026, -$112.5 million in Q4 2025, and $137.1 million in Q3 2025.